{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
A real-world survey to assess factors determining treatment of COPD with triple combination and making a choice from available options in routine clinical practice
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Survey Questionnaire Form

  1. How many patients of COPD are encountered in your routine clinical practice every month? *

  2. How are COPD patients diagnosed in your clinical practice? *
  3. How much percentage of those patients have moderate to severe COPD? *

  4. How much percentage of moderate to severe patients present with exacerbation in first visit? *

  5. What is your preferred approach for initial management of COPD patients based on severity? *
  6. Do you recommend triple therapy for all the moderate to severe patients who present with exacerbation in first visit? *

  7. How often patients with moderate to severe exacerbations followed up in your clinical practice? *

  8. Do you consider triple therapy for all the moderate to severe COPD patients who do not have history of exacerbations?*

  9. Do you recommend triple therapy for all moderate to severe COPD patients only in those with high eosinophil count (≥300 cells/µL)? *

  10. How much percentage of moderate to severe COPD patients present with high eosinophil count in your clinical practice? *

  11. How many patients of COPD who present high eosinophil count have associated asthma? *

  12. Amongst options available for triple therapy, which formulations do you prefer? *

  13. Amongst options available for triple therapy, what is preferred frequency of dosing? *

  14. Do you think once daily dosing has an advantage of better patient adherence and improved outcomes? *

  15. How much percentage of COPD patients on LABA/ICS are shifted to triple therapy in a month? *

  16. How much percentage of COPD patients on LABA/LAMA are shifted to triple therapy in a month? *

  17. How much percentage of COPD patients on triple therapy are de-escalated to LABA/LAMA in your clinical practice in a month? *

  18. How much percentage of COPD patients on triple therapy are de-escalated to LABA/ICS in your clinical practice in a month? *

  19. Which is the preferred LABA in patients with cardiac cormorbidities? *

  20. Which is the preferred LAMA based on duration of action?(Select all that apply) *

  21. While de-escalating from triple therapy to dual therapy, do you prefer to use the same molecules (ICS/LABA/LAMA) as in triple therapy? *

  22. Do you believe risk of pneumonia varies with different inhalational corticosteroids? *

  23. In your clinical practice, greatest exacerbation reduction has been seen with which combination? *

  24. In your clinical practice, greatest symptomatic improvement has been seen with which combination? *

  25. In your clinical practice, highest adherence to treatment has been seen with which combination? *

  26. In your clinical practice, most improvement in quality of life has been seen with which combination? *

  27. In your clinical practice, highest patient satisfaction has been seen with which combination? *

  28. What are the key clinical benefits of using SITT in COPD patients compared to traditional therapies?*

  29. In clinical practice, what criterias are used to choose triple therapy (Select all that apply) *

  30. Which is the patient profile that will benefit the most with triple therapy as per your clinical experience? *
  31. Do you agree that SITT decreases frequency of exacerbations and overall healthcare costs in moderate-severe COPD patients? *

  32. Do you use triple therapy in COPD patients with cardiac comorbidities? *

  33. Do you agree that there are equivalent chances of developing pneumonia with both SITT and MITT? *

  34. In moderate to severe COPD patients, what percentage will be able to use DPI (maintain flow rate>30 L/min)? *

  35. In very severe patients of COPD, is triple therapy the first line of management? *

  36. What is the role of pulmonary rehabilitation in moderate to severe COPD patients? *
  37. What is the importance of diet in moderate to severe COPD patients? *
  38. What is the importance of lung exercises in moderate to severe COPD patients? *
  39. What are the additional treatments apart from ICS/LABA/LAMA that patients of moderate to severe COPD will require? *
  40. How often patients with moderate to severe COPD have cardiac comorbidities? *

  41. Which are the common cardiac comorbidities (hypertension, Coronary artery disease, arrhythmia) seen in patients with COPD and do you recommend triple therapy in them (Yes/No)? *
    42. Common cardiac comorbidities in COPD Is triple therapy recommended in that cardiac comorbidity? (Yes/No)

  42. What are the advantages of single inhaler triple therapy (SITT) over multiple inhaled triple therapy(MITT)? *
  43. In your clinical practice, how do you manage patients of COPD not responding to triple therapy? *
  44. In your clinical practice, for how long are patients monitored/followed up to conclude that they are not responsive to triple therapy? *
  45. What are the common concerns with the long-term use of anticholinergics in triple therapy? *
  46. What are the common concerns with the long-term use of beta-2 agonists in triple therapy? *
  47. What are the common concerns with the long-term use of inhaled corticosteroids in triple therapy? *